CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibit...
Saved in:
Main Authors: | Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/3/e004410.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
by: Howard L Kaufman, et al.
Published: (2024-05-01) -
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
by: Vinay K. Pattalachinti, et al.
Published: (2025-02-01) -
When herpes zoster is not herpes: A case of statin-induced myopathy complicated by drug allergies
by: Hira Khalid Kareem, et al.
Published: (2025-01-01) -
Koi Herpes Virus (KHV) Disease
by: Kathleen H. Hartman, et al.
Published: (2004-07-01) -
Koi Herpes Virus (KHV) Disease
by: Kathleen H. Hartman, et al.
Published: (2004-07-01)